Skip to content

Lymphoproliferative Disorders After Diagnosis of Childhood Acute Lymphoblastic Leukemia/Lymphoma

Lymphoproliferative Disorders After Diagnosis of Childhood Acute Lymphoblastic Leukemia/Lymphoma

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04055558
Enrollment
40
Registered
2019-08-13
Start date
2019-08-25
Completion date
2022-03-18
Last updated
2021-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Leukemia and Lymphoma

Keywords

childhood leukemia, lymphoproliferative disorders, EBV

Brief summary

Lymphoproliferative disorders (LPD) are a major cause of morbidity and mortality in immunodeficient patients. There have been isolated case reports of patients with childhood ALL who developed LPD after ALL diagnosis, without undergoing stem cell transplantation, but data regarding such cases are limited. We propose here an international collaboration, to form a comprehensive database of children who developed LPD after diagnosis of acute lymphoblastic leukemia/lymphoma

Detailed description

Lymphoproliferative disorders (LPD) are a major cause of morbidity and mortality in immunodeficient patients. These disorders have been extensively described in the post-transplant setting, ie after hematopoietic stem cell (SCT) or solid organ (SOT) transplant. However, since the 1980's, there have been isolated case reports of patients with childhood ALL, who developed LPD after diagnosis of ALL, without undergoing SCT. Comprehensive information is unavailable regarding the prevalence, clinical manifestations, treatment, outcome and pathogenesis of such disorders in this setting. We propose here an international collaboration, to form a comprehensive database of children who developed LPD during the treatment of acute lymphoblastic leukemia/lymphoma (ALL/LBL). Information will be collected in a de-identified fashion regarding patient characteristics, leukemia and LPD characteristics, treatment and outcome. The aims of this retrospective study are: 1. To build a database of children who developed LPD after diagnosis of ALL/LBL 2. To investigate the characteristics and outcome of this disorder

Interventions

None listed

Sponsors

Israeli Society for Pediatric Hematology-Oncology
CollaboratorOTHER
International BFM Study Group
CollaboratorNETWORK
Rabin Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 30 Years
Healthy volunteers
No

Inclusion criteria

* Children and young adults treated for acute lymphoblasticleukemia/lymphoma who developed LPD after ALL/LBL diagnosis

Exclusion criteria

* age\>30 years

Design outcomes

Primary

MeasureTime frameDescription
Probability of survival1 yearAssess six-month probability of survival since LPD diagnosis

Secondary

MeasureTime frameDescription
Event-free survival5 yearsAssess 5-year event-free survival since acute lymphoblastic leukemia/lymphoma diagnosis

Countries

Israel

Contacts

Primary ContactSarah Elitzur, MD
sarhae@clalit.org.il97239253669
Backup ContactNaomi Litichever, PhD
naomilitichever@clalit.org.il97239253669

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026